According to Zhitong Finance App News, Tengsheng Pharmaceutical-B (02137) announced interim results for the six months ended June 30, 2026, with other revenue of 19.5 million yuan (RMB, same below), a year-on-year decrease of 30.6%; R&D expenses of 98.3 million yuan, a year-on-year decrease of 16.0%; loss of 101 million yuan during the period, a year-on-year decrease of 32.08%; the basic loss per share was 0.14 yuan.
According to the announcement, the decline in other revenue was mainly due to a decrease in interest income of banks by RMB 7.9 million due to a decrease in interest rates on fixed deposits. The reduction in R&D expenses was mainly due to organizational structure optimization, salary framework adjustments, and a reduction in third-party contract costs as the HBV project phase 2 research activities gradually ended, partly offset by increased investment in early detection. The decrease in losses during the period was mainly due to increased other earnings and lower operating expenses.
During and immediately after the reporting period, Tengshengbo Pharmaceutical obtained additional clinical data to support its differentiated HBV functional cure strategy, while continuing to enhance its internal discovery capabilities and advance its RNA-based technology platform. In its clinical HBV program, the company presented study completion data for the Phase 2b ENSURE study at the 2026 European Association for Liver Disease Research Conference. On July 3, the company also released the top treatment completion data for its Phase 2b ENRICH and ENHANCE study. Results from ENSURE, ENRICH, and ENHANCE studies agree that BRII-179 has the potential to improve functional healing outcomes as part of a combination treatment plan. Detailed data from the ENRICH and ENHANCE studies are expected to be released in the second half of 2026.